View in Other Languages

Avita Medical Ltd

ASX:AVH ISIN:AU000000AVH4

 Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell(R) Spray-On Skin(R), is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

  

News

Avita Medical (ASX:AVH) (AVMXY) Announces Comprehensive Participation at International Society of Burn Injuries' 17th Biennial Congress Showcasing ReCell(R) Technology

🕔10/10/2014 11:00:27 PM 5978

Avita Medical Ltd. (ASX:AVH), (OTCMKTS:AVMXY) a regenerative medicine company specializing in the treatment of wounds, scars, and skin defects, today announced that ReCell(R) will feature prominently during the scientific programme of the International Society for Burn Injuries' (ISBI) 17th Biennial Congress, in Sydney, Australia, October 12th to 16th.

Read Full Article

Avita Medical Ltd (ASX:AVH) New Chairman and Board Changes

🕔7/1/2014 8:30:47 PM 3279

Regenerative medicine company Avita Medical Ltd (ASX:AVH) (OTCMKTS:AVMXY) is pleased to welcome incoming Chairman, Lou Panaccio, who today has formally commenced his role.

Read Full Article

Chinese Regulatory Agency Formally Accepts Helicon Group's ReCell Marketing Application

🕔10/29/2007 11:45:35 AM 3226

HELICON GROUP LIMITED (ASX: HCG) announced today that the Chinese regulatory authority, the State Food and Drug Administration (SFDA) has formally accepted Helicon's dossier seeking marketing approval for the China market for ReCell(R).

Read Full Article

Clinical Cell Culture Announce Quarterly Update

🕔7/27/2007 6:36:54 PM 1733

Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 30 June 2007.

Read Full Article

Clinical Cell Culture Limited ASX: CCE - 2nd Quarter Corporate Update - Mr Bob Atwill, CEO

🕔2/1/2007 12:37:00 PM 2376

Clinical Cell Culture Limited (ASX: CCE) - 2nd Quarter Corporate Update - Mr Bob Atwill, CEO; Boardroomradio is pleased to announce that Clinical Cell Culture Limited (ASX: CCE) has published an audio file.

Read Full Article

Clinical Cell Culture To Raise A$10M - Share Purchase Plan

🕔10/25/2006 8:44:06 PM 2423

Clinical Cell Culture Ltd (ASX: CCE) today announced its intention to raise $10 million in additional capital, via a Share Purchase Plan (SPP), primarily to fund the further growth and commercialisation of the Company's lead product, ReCell (R) . The SPP is underwritten by Bell Potter Securities Limited.

Read Full Article

Clinical Cell Culture Signs Supply Agreement with CSL Ltd For Key Component of Tissue Harvesting

🕔9/28/2006 8:25:33 PM 3421

Clinical Cell Culture Ltd (ASX: CCE) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL) for the supply of Trypsin, a key component of the Company's ReCell(R) tissue harvesting device.

Read Full Article

Clinical Cell Culture Gets TGA Approval for ReCell in Australia

🕔5/26/2006 7:15:00 AM 2168

Clinical Cell Culture Ltd (ASX: CCE) today announced that the TGA (Therapeutic Goods Administration) has completed its approval process and ReCell(R) has been placed on the Australian Register of Therapeutic Goods (ARTG).

Read Full Article

Clinical Cell Culture Appoints New CEO

🕔5/19/2006 6:44:43 AM 1882

Clinical Cell Culture Ltd (ASX: CCE) announced that it has appointed Bob Atwill as its new Chief Executive Officer and a Director of the Company. C3's Chief Financial Officer Andrew Cannon also joins the Board.

Read Full Article

Clinical Cell Culture Quarterly Report - Period Ending 31 March 2006

🕔4/26/2006 6:49:36 PM 1705

Clinical Cell Culture Ltd (ASX: CCE) today released its quarterly report, Appendix 4C, for the quarter ending 31 March 2006.

Read Full Article
###

63,687 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 36) (Last 30 Days: 133) (Since Published: 13014) 

Markets ASX:AVH

Company Data

    Headquarters
  • Unit B1, Beech House, Melbourn Science Park
    Cambridge Road
    Melbourn, Royston HERTS SG8 6HB
    United Kingdom
  • Telephone
  • +44-1763-269770 
  • Fax
  • +44-1763-269780 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.avitamedical.com
  • E:
  • info.eu@avitamedical.com

Company Reports

Social Media